CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 319 enrolled
Drug / intervention
SP-624 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04479852
NCT04479852Phase 2Completed
CompareCT.gov

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Sirtsei Pharmaceuticals, Inc.·interventional·Posted Jul 21, 2020·Updated Jun 12, 2025

In Brief

A Phase 2 clinical trial evaluating SP-624 and Placebo for Major Depressive Disorder. Completed, enrolled 319 participants across 39 sites.

Detailed Summary

This is a Phase 2 clinical study evaluating the safety and effectiveness of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJul 21, 2020
Enrollment StartSep 30, 2020
Primary CompletionJun 27, 2022
Study CompletionAug 9, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 5.9 years ago

Interventions

SP-624drug

Oral capsule

Placebodrug

Oral capsule